TMC114-C213: A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.
Clinical trial NCT00650832 · COMPLETED
Trial details
- NCT number
- NCT00650832
- Sponsor
- Tibotec Pharmaceuticals, Ireland
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2003-10-01
- Primary completion
- 2005-02-01
- Enrollment
- 334
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.